Ingalls & Snyder’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,415
Closed -$5K – 485
2026
Q2
$5K Hold
11,415
– – ﹤0.01% 477
2026
Q1
$9K Hold
11,415
– – ﹤0.01% 470
2025
Q4
$15K Hold
11,415
– – ﹤0.01% 467
2025
Q3
$14K Hold
11,415
– – ﹤0.01% 481
2025
Q2
$24K Hold
11,415
– – ﹤0.01% 463
2025
Q1
$25K Sell
11,415
-2,000
-15% -$3.88K ﹤0.01% 451
2024
Q4
$21K Hold
13,415
– – ﹤0.01% 445
2024
Q3
$27K Hold
13,415
– – ﹤0.01% 453
2024
Q2
$47K Hold
13,415
– – ﹤0.01% 426
2024
Q1
$37K Buy
13,415
+2,000
+18% +$5.03K ﹤0.01% 440
2023
Q4
$19K Hold
11,415
– – ﹤0.01% 433
2023
Q3
$12K Hold
11,415
– – ﹤0.01% 434
2023
Q2
$13K Hold
11,415
– – ﹤0.01% 433
2023
Q1
$17K Hold
11,415
– – ﹤0.01% 427
2022
Q4
$29K Sell
11,415
-2,700
-19% -$8.7K ﹤0.01% 434
2022
Q3
$60K Hold
14,115
– – ﹤0.01% 419
2022
Q2
$39K Buy
+14,115
New +$56.7K ﹤0.01% 442

Other funds holding HRTX

Ingalls & Snyder's HRTX Position: Q3 2026 in Review

Ingalls & Snyder sold out of Heron Therapeutics (HRTX) in Q3 2026, closing a stake of 11,415 shares — an estimated $5K sold.

Ingalls & Snyder first reported a position in HRTX in Q2 2022 and held it in 17 quarters. The position peaked at $60K in Q3 2022. 159 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Ingalls & Snyder reported no remaining Heron Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ingalls & Snyder sold 11,415 Heron Therapeutics shares in Q3 2026, an estimated $5K.
  • Ingalls & Snyder first reported a position in Heron Therapeutics in Q2 2022 and held it in 17 quarters.
  • Ingalls & Snyder's Heron Therapeutics position peaked at $60K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Ingalls & Snyder's 13F filing for Q3 2026, filed 12 Nov 2026.